| scholarly article | Q13442814 |
| P50 | author | Ritsuko Komaki | Q64585410 |
| George R Blumenschein | Q94702986 | ||
| Chen Hu | Q39031117 | ||
| Clifford G. Robinson | Q56999688 | ||
| Raymond B Wynn | Q57615859 | ||
| P2093 | author name string | Anthony Magliocco | |
| Gregory Masters | |||
| Walter Curran | |||
| Jeffrey D Bradley | |||
| Rebecca Paulus | |||
| Yolanda I Garces | |||
| Hak Choy | |||
| Kenneth Forster | |||
| Samir Narayan | |||
| Rakesh Gaur | |||
| Puneeth Iyengar | |||
| Jeffrey Bogart | |||
| Joanne Meng | |||
| Christopher Koprowski | |||
| Steven Schild | |||
| Jonathan Beitler | |||
| Vivek Kavadi | |||
| P2860 | cites work | Repeated assessment of results in clinical trials of cancer treatment | Q69950375 |
| A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group | Q72135645 | ||
| A comment on futility monitoring | Q74570755 | ||
| Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer | Q83858463 | ||
| Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design | Q24569560 | ||
| Nonparametric Estimation from Incomplete Observations | Q25938997 | ||
| EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study | Q27851683 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck | Q29619277 | ||
| A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117 | Q33847603 | ||
| Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117. | Q33897625 | ||
| Evaluation of survival data and two new rank order statistics arising in its consideration | Q34054360 | ||
| Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324 | Q35023433 | ||
| Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. | Q35268628 | ||
| Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group | Q44070976 | ||
| Structural basis for inhibition of the epidermal growth factor receptor by cetuximab | Q45345151 | ||
| Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. | Q46589628 | ||
| The randomization and stratification of patients to clinical trials | Q52895239 | ||
| Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer. | Q53442508 | ||
| P433 | issue | 2 | |
| P921 | main subject | lung cancer | Q47912 |
| adaptive radiation therapy | Q180507 | ||
| carboplatin | Q415588 | ||
| cetuximab | Q420296 | ||
| paclitaxel | Q423762 | ||
| P304 | page(s) | 187-199 | |
| P577 | publication date | 2015-01-16 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two facto | |
| P478 | volume | 16 |
| Q91802369 | "Dose of the day" based on cone beam computed tomography and deformable image registration for lung cancer radiotherapy |
| Q35870847 | (18)F-FDG avid volumes on pre-radiotherapy FDG PET as boost target delineation in non-small cell lung cancer. |
| Q27002509 | 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer |
| Q33786722 | A Dosimetric Comparison of Dose Escalation with Simultaneous Integrated Boost for Locally Advanced Non-Small-Cell Lung Cancer |
| Q99237996 | A Prospective Study of Early Radiation Associated Cardiac Toxicity Following Neoadjuvant Chemoradiation for Distal Esophageal Cancer |
| Q36672750 | A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients |
| Q28079625 | A critical review of recent developments in radiotherapy for non-small cell lung cancer |
| Q64071662 | A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer |
| Q39029314 | A geometric atlas to predict lung tumor shrinkage for radiotherapy treatment planning |
| Q92067247 | A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer |
| Q64286235 | A novel approach for salvage treatment of non-small-cell lung cancer: percutaneous CT fluoroscopy-guided permanent seed brachytherapy for salvage treatment of lung cancer: long-term results of a case series |
| Q97649635 | A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN 14-179 |
| Q37716645 | A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer |
| Q92424817 | A phase II study of concurrent nab-paclitaxel/carboplatin combined with thoracic radiotherapy in locally advanced squamous cell lung cancer |
| Q59799824 | A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer |
| Q55114654 | A promising result of locoregional tumor control with biologically adaptive radiotherapy in patients with locally advanced non-small cell lung cancer. |
| Q52716547 | A quality control method for intensity-modulated radiation therapy planning based on generalized equivalent uniform dose. |
| Q57157837 | A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L |
| Q52649579 | A retrospective study of shrinking field radiation therapy during chemoradiotherapy in stage III non-small cell lung cancer. |
| Q38717425 | A systematic review of the cost and cost-effectiveness studies of proton radiotherapy |
| Q92993536 | Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up |
| Q35997579 | Accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase II |
| Q64229465 | Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study |
| Q41670890 | Acute and Late Toxicities of Concurrent Chemoradiotherapy for Locally-Advanced Non-Small Cell Lung Cancer |
| Q51610252 | Adaptation requirements due to anatomical changes in free-breathing and deep-inspiration breath-hold for standard and dose-escalated radiotherapy of lung cancer patients. |
| Q47794635 | Adaptive radiotherapy for locally advanced non-small cell lung cancer: dosimetric gain and treatment outcome prediction |
| Q57172945 | Advanced radiation techniques for locally advanced non-small cell lung cancer: intensity-modulated radiation therapy and proton therapy |
| Q89696569 | Advances in Preclinical Research Models of Radiation-Induced Cardiac Toxicity |
| Q64325572 | Advances in proton therapy in lung cancer |
| Q58804844 | Advances in radiation therapy for thoracic malignancies |
| Q33645619 | Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy |
| Q58804831 | Advances in the use of motion management and image guidance in radiation therapy treatment for lung cancer |
| Q41201725 | Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients |
| Q36818873 | An Analysis of Plan Robustness for Esophageal Tumors: Comparing Volumetric Modulated Arc Therapy Plans and Spot Scanning Proton Planning |
| Q64948337 | An esophagus-sparing technique to limit radiation esophagitis in locally advanced non-small cell lung cancer treated by simultaneous integrated boost intensity-modulated radiotherapy and concurrent chemotherapy. |
| Q48714993 | An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging |
| Q47718840 | Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer |
| Q38713045 | Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency. |
| Q37329842 | Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize |
| Q89568332 | Anticancer therapy and lung injury: molecular mechanisms |
| Q91906482 | Association of lung and heart dose with survival in patients with non-small cell lung cancer underwent volumetric modulated arc therapy |
| Q48137260 | Australia and New Zealand Faculty of Radiation Oncology Lung Interest Cooperative: 2015 consensus guidelines for the use of advanced technologies in the radiation therapy treatment of locally advanced non-small cell lung cancer |
| Q57279495 | Automatic segmentation of cardiac substructures from noncontrast CT images: accurate enough for dosimetric analysis? |
| Q38705244 | Autophagy enhanced the radioresistance of non-small cell lung cancer by regulating ROS level under hypoxia condition |
| Q47887111 | Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer |
| Q49256406 | Before or After: Evolving Neoadjuvant Approaches to Locally Advanced Non-Small Cell Lung Cancer |
| Q104135107 | Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited) |
| Q99408579 | Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations |
| Q47344087 | Blood-based biomarkers for precision medicine in lung cancer: precision radiation therapy |
| Q55036513 | Breaking the dose ceiling: proton therapy for locally advanced non-small cell lung cancer. |
| Q38645182 | Breast cancer therapy-associated cardiovascular disease |
| Q52984769 | Can the probability of radiation esophagitis be reduced without compromising lung tumor control: A radiobiological modeling study. |
| Q47171167 | Carbon-ion radiotherapy for patients with advanced stage non-small-cell lung cancer at multicenters |
| Q53914428 | Cardiac Dose and Survival After Stereotactic Body Radiotherapy for Early-stage Non-Small-cell Lung Cancer. |
| Q50795251 | Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer. |
| Q97073736 | Cardiac MRI utilizing late gadolinium enhancement (LGE) and T1 mapping in the detection of radiation induced heart disease |
| Q48707805 | Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. |
| Q49304879 | Cardiac atlas development and validation for automatic segmentation of cardiac substructures. |
| Q99607620 | Cardiac radiation dose predicts survival in esophageal squamous cell carcinoma treated by definitive concurrent chemotherapy and intensity modulated radiotherapy |
| Q91714498 | Cardiovascular Damage Associated With Chest Irradiation |
| Q92980801 | Cardiovascular Toxicities of Radiation Therapy |
| Q48506830 | Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging |
| Q38746213 | Charged-particle therapy in cancer: clinical uses and future perspectives |
| Q36842180 | Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer. |
| Q40701391 | Clinical outcome of image-guided adaptive radiotherapy in the treatment of lung cancer patients |
| Q91844914 | Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer |
| Q61800505 | Clinical outcomes of carbon-ion radiotherapy for locally advanced non-small-cell lung cancer |
| Q64073728 | Clinical significance of pretreatment tumor growth rate for locally advanced non-small cell lung cancer |
| Q64946952 | Combined Chemoradiotherapy-induced Weight Loss Decreases Survival in Locally Advanced Non-small Cell Lung Cancer Patients. |
| Q94525641 | Combined Therapeutic Effects of 131I-Labeled and 5Fu-Loaded Multifunctional Nanoparticles in Colorectal Cancer |
| Q60939646 | Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity? |
| Q58804834 | Combining immunotherapy with radiation therapy in thoracic oncology |
| Q61804646 | Combining stereotactic body radiation therapy with immunotherapy: current data and future directions |
| Q47126832 | Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505). |
| Q64105066 | Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis |
| Q36447645 | Comparison of Toxicity Between Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy for Locally Advanced Non-small-cell Lung Cancer |
| Q92727137 | Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study |
| Q36051734 | Comparison of once daily radiotherapy to 60 Gy and twice daily radiotherapy to 45 Gy for limited stage small-cell lung cancer |
| Q41431618 | Comparison of photon volumetric modulated arc therapy, intensity-modulated proton therapy, and intensity-modulated carbon ion therapy for delivery of hypo-fractionated thoracic radiotherapy |
| Q55155303 | Comparison of proton therapy and intensity modulated photon radiotherapy for locally advanced non-small cell lung cancer: considerations for optimal trial design. |
| Q92485045 | Comparison of the effects of radiotherapy doses of 50.4 Gy and 60 Gy on outcomes of chemoradiotherapy for thoracic esophageal cancer: subgroup analysis based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan |
| Q37605623 | Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy |
| Q88477815 | Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group |
| Q40339097 | Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study |
| Q86846066 | Cone-beam CT-guided radiotherapy in the management of lung cancer: Diagnostic and therapeutic value |
| Q41081663 | Cons: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with inoperable large volume stage III non-small cell lung cancer |
| Q55345367 | Consolidation of immunotherapy becomes new standard of care in unresectable stage III non-small cell lung cancer. |
| Q53045959 | Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. |
| Q38706315 | Consuming a Ketogenic Diet while Receiving Radiation and Chemotherapy for Locally Advanced Lung Cancer and Pancreatic Cancer: The University of Iowa Experience of Two Phase 1 Clinical Trials. |
| Q38400856 | Correlation analysis of [18F]fluorodeoxyglucose and [18F]fluoroazomycin arabinoside uptake distributions in lung tumours during radiation therapy |
| Q89710930 | Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab |
| Q37714576 | DART-bid for loco-regionally advanced NSCLC : Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints. |
| Q58616560 | Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial |
| Q51542704 | Deep inspiration breath-hold volumetric modulated arc radiotherapy decreases dose to mediastinal structures in locally advanced lung cancer. |
| Q47442495 | Deep reinforcement learning for automated radiation adaptation in lung cancer. |
| Q38902680 | Definitive Radiotherapy for Local Recurrence of NSCLC After Surgery |
| Q36128358 | Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer |
| Q39246472 | Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence |
| Q59127541 | Delineation of lung cancer with FDG PET/CT during radiation therapy |
| Q54941414 | Developing a Reliable Mouse Model for Cancer Therapy-Induced Cardiovascular Toxicity in Cancer Patients and Survivors. |
| Q41550760 | Developing and Validating a Survival Prediction Model for NSCLC Patients Through Distributed Learning Across 3 Countries. |
| Q58561764 | Development and validation of a decision support tool to select IMRT as radiotherapy treatment planning modality for patients with locoregionally advanced non-small cell lung cancers (NSCLC) |
| Q49676347 | Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo |
| Q37528298 | Did dose escalated radiotherapy in stage III non-small cell lung cancer improve overall survival? |
| Q47779285 | Difference in target definition using three different methods to include respiratory motion in radiotherapy of lung cancer. |
| Q89757806 | Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two p |
| Q33574732 | Does Motion Assessment With 4-Dimensional Computed Tomographic Imaging for Non-Small Cell Lung Cancer Radiotherapy Improve Target Volume Coverage? |
| Q39378862 | Dose and Fractionation in Radiation Therapy of Curative Intent for Non-Small Cell Lung Cancer: Meta-Analysis of Randomized Trials |
| Q38549486 | Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line? |
| Q37098334 | Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non-small cell lung cancer |
| Q49199019 | Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy. |
| Q92984857 | Doses of radiation to the pericardium, instead of heart, are significant for survival in patients with non-small cell lung cancer |
| Q92594172 | Dosimetric Comparison of Lung-Sparing Radiation Therapy between Volumetric Arc Therapy and Helical Tomotherapy for Unresectable Malignant Pleural Mesothelioma |
| Q41039681 | Dosimetric advantages of intensity modulated radiation therapy in locally advanced lung cancer |
| Q52855166 | Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced non-small cell lung cancer. |
| Q41257238 | Dosimetric comparison of carbon ion and X-ray radiotherapy for Stage IIIA non-small cell lung cancer |
| Q47346625 | Dosimetric comparison of the helical tomotherapy, volumetric-modulated arc therapy and fixed-field intensity-modulated radiotherapy for stage IIB-IIIB non-small cell lung cancer |
| Q47972027 | Dosimetric predictors for acute esophagitis during radiation therapy for lung cancer: Results of a large statewide observational study. |
| Q55192895 | Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. |
| Q55105262 | Durvalumab for non-resectable stage IIIB non-small cell lung cancer-a small step or a big leap? |
| Q55304879 | Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. |
| Q89141012 | EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy |
| Q38552978 | EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection |
| Q36056706 | Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer |
| Q50128100 | Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. |
| Q96305368 | Early Outcomes of Patients With Locally Advanced Non-small Cell Lung Cancer Treated With Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiation Therapy: The Mayo Clinic Experience |
| Q38821679 | Early cardiac perfusion defects after left-sided radiation therapy for breast cancer: is there a volume response? |
| Q55412836 | Editorial: Controversies in the Local Management of Lung Cancer. |
| Q43169494 | Editorial: Image-Guided Radiotherapy for Effective Radiotherapy Delivery |
| Q38376135 | Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial. |
| Q38378765 | Effect of accurate heart delineation on cardiac dose during the CONVERT trial |
| Q91606046 | Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial |
| Q38641099 | Emerging Role of MRI for Radiation Treatment Planning in Lung Cancer |
| Q41475564 | Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy |
| Q35768924 | Esophagus and Contralateral Lung-Sparing IMRT for Locally Advanced Lung Cancer in the Community Hospital Setting |
| Q36866800 | Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC |
| Q94544900 | Evaluating dosimetric constraints for carbon ion radiotherapy in the treatment of locally advanced pancreatic cancer |
| Q38401906 | Evolution of [18F]fluorodeoxyglucose and [18F]fluoroazomycin arabinoside PET uptake distributions in lung tumours during radiation therapy |
| Q36153707 | Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot s |
| Q57799597 | FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer |
| Q29248450 | Feasibility and efficacy of helical intensity-modulated radiotherapy for stage III non-small cell lung cancer in comparison with conventionally fractionated 3D-CRT |
| Q40614319 | Feasibility and efficacy of salvage lung resection after definitive chemoradiation therapy for Stage III non-small-cell lung cancer. |
| Q37427038 | Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator. |
| Q55001587 | Feasibility of stereotactic body radiotherapy for locally-advanced non-small cell lung cancer. |
| Q89572724 | Feasibility of stereotactic radiotherapy for lung lesions and conventional radiotherapy for nodal areas in primary lung malignancies |
| Q42668963 | Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation |
| Q39041541 | From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage? |
| Q57810775 | Fucoidan Inhibits Radiation-Induced Pneumonitis and Lung Fibrosis by Reducing Inflammatory Cytokine Expression in Lung Tissues |
| Q38401313 | Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy |
| Q57456283 | Functionally impaired Tfh cells induce regulatory B cells and CD14 HLA-DR cells differentiation in non-small cell lung cancer |
| Q40951849 | GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer |
| Q47189971 | Health care disparities among octogenarians and nonagenarians with stage III lung cancer |
| Q55135101 | Heart Dose and Outcomes in Radiation Treatment for Esophageal Cancer. |
| Q38641174 | Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma |
| Q92356134 | Heart V5 predicts cardiac events in unresectable lung cancer patients undergoing chemoradiation |
| Q64092344 | Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy |
| Q47779231 | Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial. |
| Q47757777 | Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer |
| Q37720721 | Highlights from the ecancer Future Horizons in Lung Cancer conference, 1-2 September 2016: Focusing on the future of treatment for NSCLC and SCLC |
| Q89017230 | How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience |
| Q37470072 | Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation |
| Q97517596 | Hypofractionated Accelerated Concurrent Chemoradiotherapy in Inoperable Stage III Non-small Cell Lung Cancer: SOCCAR. A Large Single-Centre Experience |
| Q60922809 | Hypoxia imaging in upper gastrointestinal tumors and application to radiation therapy |
| Q37123650 | IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer. |
| Q52990447 | IMRT and 3D conformal radiotherapy with or without elective nodal irradiation in locally advanced NSCLC: A direct comparison of PET-based treatment planning. |
| Q57022957 | Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database |
| Q40102857 | Identifying the Optimal Radiation Dose in Locally Advanced Non-Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy |
| Q90325443 | Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial |
| Q89884254 | Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives |
| Q56891772 | Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer |
| Q55322253 | Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care? |
| Q38514566 | Immunotherapy for non-small-cell lung cancer: the past 10 years |
| Q64998544 | Immunotherapy in inoperable stage III non-small cell lung cancer: a review. |
| Q38549598 | Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation? |
| Q54978827 | Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages? |
| Q89518844 | Impact of Definitive Radiotherapy and Surgical Debulking on Treatment Outcome and Prognosis for Locally Advanced Masaoka-Koga stage III Thymoma |
| Q64881434 | Impact of Esophageal Motion on Dosimetry and Toxicity With Thoracic Radiation Therapy. |
| Q39052564 | Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial |
| Q99712001 | Impact of Radiation Dose on Survival for Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemoradiotherapy |
| Q61455695 | Impact of metformin use on survival outcomes in non-small cell lung cancer treated with platinum |
| Q93239497 | Impact of modern radiotherapy techniques on survival outcomes for unselected patients with large volume non-small cell lung cancer |
| Q95260276 | Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)-a German radiation oncology survey |
| Q87898981 | Improve dosimetric outcome in stage III non-small-cell lung cancer treatment using spot-scanning proton arc (SPArc) therapy |
| Q39510875 | Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database. |
| Q30382413 | Improving survival of patients with locally advanced non-small-cell cancer remains a challenge: comment to PROCLAIM. |
| Q40080098 | Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. |
| Q92092329 | Incidence and risk factors of interstitial lung disease of patients with head and neck cancer treated with cetuximab |
| Q90010770 | Inclusiveness and ethical considerations for observational, translational, and clinical cancer health disparity research |
| Q36030323 | Increased Biological Effective Dose of Radiation Correlates with Prolonged Survival of Patients with Limited-Stage Small Cell Lung Cancer: A Systematic Review |
| Q41613080 | Individual isotoxic radiation dose escalation based on V20 and advanced technologies benefits unresectable stage III non-small cell lung cancer patients treated with concurrent chemoradiotherapy: long term follow-up |
| Q39135164 | Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer. |
| Q30238797 | Influence of dose and fractionation in radiation therapy of curative intent for non-small cell lung cancer |
| Q92162685 | Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis |
| Q38754603 | Inhibition on Numb/Notch signal pathway enhances radiosensitivity of lung cancer cell line H358. |
| Q39748985 | Institutional Enrollment and Survival Among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617. |
| Q64243939 | Integrating Small Animal Irradiators withFunctional Imaging for Advanced Preclinical Radiotherapy Research |
| Q38771934 | Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. |
| Q38623448 | Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity |
| Q57785727 | Interim Analysis of a Two-Institution, Prospective Clinical Trial of 4DCT-Ventilation-based Functional Avoidance Radiation Therapy |
| Q92281416 | Intrafractional Displacement of Cardiac Substructures Among Patients With Mediastinal Lymphoma or Lung Cancer |
| Q54981563 | Ionizing Radiation Induces Endothelial Inflammation and Apoptosis via p90RSK-Mediated ERK5 S496 Phosphorylation. |
| Q36609568 | Is a Clinical Target Volume (CTV) Necessary in the Treatment of Lung Cancer in the Modern Era Combining 4-D Imaging and Image-guided Radiotherapy (IGRT)? |
| Q48546289 | Is a clinical target volume (CTV) necessary for locally advanced non-small cell lung cancer treated with intensity-modulated radiotherapy? -a dosimetric evaluation of three different treatment plans |
| Q89116529 | Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer? |
| Q37618701 | Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy? |
| Q91587573 | Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach? |
| Q88288584 | Is tumor volume reduction during radiotherapy prognostic relevant in patients with stage III non-small cell lung cancer? |
| Q90325417 | Less is more in radiotherapy target volume planning: lessons from the PET-plan trial |
| Q36829707 | Limiting the risk of cardiac toxicity with esophageal-sparing intensity modulated radiotherapy for locally advanced lung cancers |
| Q48181398 | Local failure after radical radiotherapy of non-small cell lung cancer in relation to the planning FDG-PET/CT. |
| Q64108530 | Locally Advanced Non Small Cell Lung Cancer: The Case for Radiation Dose De-escalation in the Management of the Mediastinum |
| Q38558894 | Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration |
| Q90100983 | Locally Advanced, Unresectable Non-Small Cell Lung Cancer |
| Q49413036 | Locally advanced non-small cell lung cancer treatment: another step forward |
| Q55286402 | Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance? |
| Q50862063 | Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. |
| Q91759003 | Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer |
| Q39019487 | Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). |
| Q36729045 | Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer |
| Q64890174 | Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. |
| Q40502254 | Loss of Nrf2 promotes alveolar type 2 cell loss in irradiated, fibrotic lung |
| Q58104323 | Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer |
| Q47445024 | Lower Incidence of Esophagitis in the Elderly Undergoing Definitive Radiation Therapy for Lung Cancer |
| Q88915500 | Lung IMRT planning with automatic determination of beam angle configurations |
| Q45060689 | Lung and Heart Dose Variability During Radiation Therapy of Non-Small Cell Lung Cancer. |
| Q38856196 | Lung cancer radiation therapy in Australia and New Zealand: Patterns of practice. |
| Q38940816 | Lung cancer: current therapies and new targeted treatments |
| Q91795860 | Machine learning highlights the deficiency of conventional dosimetric constraints for prevention of high-grade radiation esophagitis in non-small cell lung cancer treated with chemoradiation |
| Q47108915 | Magnetic resonance imaging in precision radiation therapy for lung cancer |
| Q47162424 | Management of non-small cell lung cancer with EGFR mutation: the role of radiotherapy in the era of tyrosine kinase inhibitor therapy-opportunities and challenges |
| Q90028604 | Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices |
| Q39521003 | Meta-analysis of the incidence and risk of arterial and venous thromboembolic events associated with anti-EGFR agents in non-small-cell lung cancer patients |
| Q39373649 | Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235. |
| Q26767182 | Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma |
| Q90615945 | Multi-Institutional Validation of a Knowledge-Based Planning Model for Patients Enrolled in RTOG 0617: Implications for Plan Quality Controls in Cooperative Group Trials |
| Q33583931 | Multidisciplinary team approach for the management of patients with locally advanced non-small cell lung cancer: searching the evidence to guide the decision |
| Q38930358 | Multimodality Therapy for NSCLC. |
| Q55070937 | NF-κB inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair. |
| Q37745120 | NLRP3 inflammasome activation mediates radiation-induced pyroptosis in bone marrow-derived macrophages |
| Q55020992 | Necitumumab in squamous non-small-cell lung cancer: how to move forward? |
| Q93083879 | Neoadjuvant PD-1 blockade in non-small cell lung cancer: what else do we need to do? |
| Q52338636 | Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer. |
| Q40175347 | Neoadjuvant combination chemotherapy for unresectable stage III non-small cell lung cancer |
| Q41561562 | New dose constraint reduces radiation-induced fatal pneumonitis in locally advanced non-small cell lung cancer patients treated with intensity-modulated radiotherapy |
| Q89540121 | Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial |
| Q38763104 | Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy |
| Q35669846 | Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid). |
| Q26775388 | Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies |
| Q92286712 | Oesophageal Cancer: Conformal Radiotherapy vs. Hybrid-VMAT Technique With Two Different Treatment Planning Systems |
| Q99565907 | Optimal radiation dose in the neoadjuvant management of esophageal cancer |
| Q92306391 | Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy |
| Q58786273 | Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancer |
| Q58804840 | Optimizing radiation dose and fractionation for the definitive treatment of locally advanced non-small cell lung cancer |
| Q88253963 | Outcome and toxicity of intensity modulated radiotherapy with simultaneous integrated boost in locally advanced non-small cell lung cancer patients |
| Q36649532 | PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules. |
| Q99582968 | PET-Plan: potential for dose escalation by target volume reduction in locally advanced NSCLC |
| Q90346196 | PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer |
| Q37417131 | PRONTOX - proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung carcinomas (NSCLC): study protocol for a randomised controlled trial |
| Q54963486 | Pacific trial: a new ocean or an abnormal wave? |
| Q55073985 | Particle therapy in non-small cell lung cancer. |
| Q38682031 | Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer |
| Q64256380 | Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer |
| Q52682575 | Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). |
| Q89799444 | Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial |
| Q37516506 | Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer |
| Q55284746 | Phase I study of concurrent and consolidation cisplatin and docetaxel chemotherapy with thoracic radiotherapy in non-small cell lung cancer. |
| Q92947593 | Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research |
| Q33688658 | Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers |
| Q42176071 | Polymorphisms in BMP2/BMP4, with estimates of mean lung dose, predict radiation pneumonitis among patients receiving definitive radiotherapy for non-small cell lung cancer |
| Q36368864 | Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. |
| Q47777467 | Positron Emission Tomography-Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer |
| Q48920934 | Potential for adaptive dose escalation in radiotherapy for patients with locally advanced non-small-cell lung cancer in a low mid income setting. |
| Q47142302 | Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal Cancer. |
| Q42052388 | Practical and theoretical implications of weight gain in advanced non-small cell lung cancer patients |
| Q104135108 | Practical implications to contemplate when considering radical therapy for stage III non-small-cell lung cancer |
| Q56528378 | Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie? |
| Q54963061 | Precision radiotherapy for patients with locally advanced non-small cell lung cancer in the era of immunotherapy and precision medicine. |
| Q47342475 | Prediction of Radiation Esophagitis in Non-Small Cell Lung Cancer Using Clinical Factors, Dosimetric Parameters, and Pretreatment Cytokine Levels |
| Q42659931 | Prediction of Treatment Response for Combined Chemo- and Radiation Therapy for Non-Small Cell Lung Cancer Patients Using a Bio-Mathematical Model |
| Q89763682 | Predictive model of the first failure pattern in patients receiving definitive chemoradiotherapy for inoperable locally advanced non-small cell lung cancer (LA-NSCLC) |
| Q90427294 | Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer |
| Q36169891 | Preliminary results of proton-beam therapy for stage III non-small-cell lung cancer |
| Q93112000 | Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08) |
| Q90603658 | Preoperative radiation may improve the outcomes of resectable IIIA/N2 non-small-cell lung cancer patients: A propensity score matching-based analysis from surveillance, epidemiology, and end results database |
| Q37180546 | Pretreatment 18F-FDG PET Textural Features in Locally Advanced Non-Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235. |
| Q95723917 | Prognostic Factors in Stage III Non-Small-Cell Lung Cancer Patients |
| Q49713310 | Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer |
| Q33743705 | Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer |
| Q58120049 | Prognostic and Added Value of Echocardiographic Strain for Prediction of Adverse Outcomes in Patients with Locally Advanced Non-Small Cell Lung Cancer after Radiotherapy |
| Q64284071 | Prognostic significance of lung radiation dose in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy |
| Q64287366 | Prognostic value of TIM-1 expression in human non-small-cell lung cancer |
| Q33648808 | Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients. |
| Q35959380 | Proliferation PET image to characterize pathological spatial features in patients with non-small cell lung cancer: a pilot study. |
| Q36874790 | Pros: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer |
| Q36818897 | Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study. |
| Q38669946 | Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study |
| Q38543109 | Proton Beam Therapy for Non-Small Cell Lung Cancer: Current Clinical Evidence and Future Directions |
| Q96946000 | Proton beam or photon beam radiotherapy in the treatment of non-small-cell lung cancer |
| Q38830371 | Proton beam therapy in Japan: current and future status |
| Q38786895 | Proton therapy - Present and future |
| Q55041495 | Proton therapy for post-operative radiation therapy of non-small cell lung cancer. |
| Q55358944 | Proton therapy for small cell lung cancer. |
| Q54968869 | Proton therapy for thoracic reirradiation of non-small cell lung cancer. |
| Q55420726 | Proton therapy in non-small cell lung cancer. |
| Q38678310 | Pulmonary Function Changes After Radiotherapy for Lung or Esophageal Cancer: A Systematic Review Focusing on Dose-Volume Parameters |
| Q92119093 | Pulmonary function decreases moderately after accelerated high-dose irradiation for stage III non-small cell lung cancer |
| Q36673860 | Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial |
| Q37706118 | Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach |
| Q50139034 | Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis |
| Q55038620 | Radiation Oncology in the 21st Century: Prospective Randomized Trials That Changed Practice… or Didn't! |
| Q30278410 | Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized Trials |
| Q91869235 | Radiation injury to cardiac arteries and myocardium is reduced by soy isoflavones |
| Q57062254 | Radiation-Drug Combinations to Improve Clinical Outcomes and Reduce Normal Tissue Toxicities: Current Challenges and New Approaches: Report of the Symposium Held at the 63rd Annual Meeting of the Radiation Research Society, 15-18 October 2017; Cancun |
| Q45058787 | Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016. |
| Q37643563 | Radiation-induced esophagitis in lung cancer |
| Q30244586 | Radiation-induced heart disease in lung cancer radiotherapy: A dosimetric update |
| Q40346974 | Radical hypo-fractionated radiotherapy with volumetric modulated arc therapy in lung cancer : A retrospective study of elderly patients with stage III disease. |
| Q26765355 | Radio(chemo)therapy in locally advanced nonsmall cell lung cancer |
| Q64279738 | Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study |
| Q47155121 | Radiomics in precision medicine for lung cancer. |
| Q42363788 | Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: "MTD" or "ALARA"? |
| Q28068005 | Radiotherapy Techniques and Radiation Pneumonitis: A Lot To A Little Or A Little To A Lot? |
| Q87060874 | Radiotherapy dose and fractionation for stage III NSCLC |
| Q38564088 | Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors |
| Q38718558 | Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839. |
| Q104135106 | Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer |
| Q41081446 | Rebuttal from Prof. Kong and Dr. Rabatic. |
| Q97524887 | Registering Study Analysis Plans (SAPs) Before Dissecting Your Data-Updating and Standardizing Outcome Modeling |
| Q58804832 | Reirradiation for locoregionally recurrent non-small cell lung cancer |
| Q52878867 | Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease : A multi-institutional treatment recommendation. |
| Q97418528 | Relationship between radiation doses to heart substructures and radiation pneumonitis in patients with thymic epithelial tumors |
| Q37151103 | Repression of the autophagic response sensitises lung cancer cells to radiation and chemotherapy |
| Q37701159 | Reproducibility of the EGFR immunohistochemistry scores for tumor samples from patients with advanced non-small cell lung cancer |
| Q47115640 | Research in imaging/biomarkers for precision medicine in lung cancer: National Cancer Institute funding opportunities |
| Q55113219 | Resolution of atelectasis during radiochemotherapy of lung cancer with serious implications for further treatment. A case report. |
| Q37597937 | Results of a Single Institution Experience with Dose-Escalated Chemoradiation for Locally Advanced Unresectable Non-Small Cell Lung Cancer |
| Q48282380 | Rethink radiotherapy - BIGART 2017. |
| Q92016948 | Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer |
| Q48226075 | Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial. |
| Q48365205 | Risk of major cardiac events following adjuvant proton versus photon radiation therapy for patients with thymic malignancies |
| Q38841400 | Robust Intratumor Partitioning to Identify High-Risk Subregions in Lung Cancer: A Pilot Study |
| Q37484854 | Role of multimodality therapy in cIIIA-N2 non-small cell lung cancer: perspective |
| Q51825980 | Role of surgery in clinical N2 non-small-cell lung cancer: a pro and con debate; the 'con' viewpoint. |
| Q95473377 | SABR versus conventional fractionation regimens in NSCLC - Authors' reply |
| Q93185774 | SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018) |
| Q36400216 | SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015. |
| Q57297764 | Salvage surgery for recurrent or persistent tumour after radical (chemo)radiotherapy for locally advanced non-small cell lung cancer: a systematic review |
| Q48192357 | Salvage thoracic surgery in patients with lung cancer: potential indications and benefits. |
| Q41114856 | Savior or not: ADAM17 inhibitors overcome radiotherapy-resistance in non-small cell lung cancer |
| Q96305364 | Scanning Beam Proton Therapy versus Photon IMRT for Stage III Lung Cancer: Comparison of Dosimetry, Toxicity, and Outcomes |
| Q47428325 | Serum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer |
| Q64901505 | Serum microRNA guiding personalized radiation therapy in non-small cell lung cancer. |
| Q48684136 | Should regional ventilation function be considered during radiation treatment planning to prevent radiation-induced complications? |
| Q38996898 | Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811. |
| Q92072927 | Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients |
| Q49724223 | Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cance |
| Q41472312 | Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study |
| Q42356542 | Simultaneously modulated accelerated radiation therapy reduces severe oesophageal toxicity in concomitant chemoradiotherapy of locally advanced non-small-cell lung cancer. |
| Q38712700 | Squamous-cell carcinoma of the anus: progress in radiotherapy treatment |
| Q91630556 | Stage III Non-Small-Cell Lung Cancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort |
| Q53822924 | Standard of care in high-dose radiotherapy for localized non-small cell lung cancer. |
| Q96305389 | Stereotactic Body Radiation Therapy to a Splenic Metastasis in Oligoprogressive Non-small Cell Lung Cancer |
| Q64891069 | Stop hedging your bets: reasons for non-adherence to a tri-modality regimen in the treatment of esophageal cancer in a multidisciplinary setting. |
| Q47117242 | Study on orally delivered paclitaxel nanocrystals: modification, characterization and activity in the gastrointestinal tract. |
| Q89997794 | Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib |
| Q38834703 | Superior sulcus non-small cell lung carcinoma: A comparison of IMRT and 3D-RT dosimetry. |
| Q91724690 | Surgery after chemoradiotherapy in patients with stage III (N2 or N3, excluding T4) non-small-cell lung cancer: a systematic review |
| Q50088484 | Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest |
| Q90159883 | Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy |
| Q92281451 | Synchronous Oligometastatic Non-small Cell Lung Cancer Managed With Curative-Intent Chemoradiation Therapy: Long-term Outcomes From a Single Institution |
| Q56346293 | TUSC3 accelerates cancer growth and induces epithelial-mesenchymal transition by upregulating claudin-1 in non-small-cell lung cancer cells |
| Q38815297 | Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). |
| Q61805942 | Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response |
| Q47769995 | Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome |
| Q41339882 | Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials |
| Q64071654 | Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy |
| Q47138854 | Temporal and spatial dose distribution of radiation pneumonitis after concurrent radiochemotherapy in stage III non-small cell cancer patients |
| Q38620687 | The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer. |
| Q48201241 | The NARLAL2 dose escalation trial: dosimetric implications of inter-fractional changes in organs at risk |
| Q41455781 | The Potential of Heavy-Ion Therapy to Improve Outcomes for Locally Advanced Non-Small Cell Lung Cancer. |
| Q90182046 | The Role of Mitochondrial Dysfunction in Radiation-Induced Heart Disease: From Bench to Bedside |
| Q57172942 | The current state of oligometastatic and oligoprogressive non-small cell lung cancer |
| Q36287297 | The effect of induction chemotherapy in patients with locally advanced nonsmall cell lung cancer who received chemoradiotherapy: A systematic review and meta-analysis |
| Q90346435 | The emerging role of proton therapy for esophagus cancer |
| Q49333936 | The evolution of proton beam therapy: Current and future status |
| Q90175125 | The evolving role of radiotherapy in non-small cell lung cancer |
| Q58804836 | The evolving role of radiotherapy in the management of small cell lung cancer |
| Q26741041 | The impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced non-small cell lung cancer: a literature review and pooled analysis |
| Q90392206 | The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy |
| Q91910816 | The radiation dose tolerance of the brachial plexus: A systematic review and meta-analysis |
| Q38663176 | The relationship between cardiac radiation dose and mediastinal lymph node involvement in stage III non-small cell lung cancer patients |
| Q93336641 | The risk variant rs884225 within EGFR impairs miR-103a-3p's anti-tumourigenic function in non-small cell lung cancer |
| Q37589335 | The use of dose-escalated radiation for locally advanced non-small cell lung cancer in the U.S., 2004-2013. |
| Q37642455 | Therapeutic management options for stage III non-small cell lung cancer |
| Q33428648 | Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer. |
| Q38374064 | Time and Effort Required for Tissue Acquisition and Submission in Lung Cancer Clinical Trials |
| Q57187264 | Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer |
| Q47163187 | Treating locally advanced lung cancer with a 1.5T MR-Linac - Effects of the magnetic field and irradiation geometry on conventionally fractionated and isotoxic dose-escalated radiotherapy. |
| Q39030907 | Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). |
| Q64973779 | Treatment for non-small-cell lung cancer and circulating tumor cells. |
| Q64287205 | Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC |
| Q38930349 | Treatment: Radiation Therapy |
| Q64907648 | Trends and Patterns of Disparities in Burden of Lung Cancer in the United States, 1974-2015. |
| Q41115829 | Update in Lung Cancer 2015. |
| Q36433810 | Use a survival model to correlate single-nucleotide polymorphisms of DNA repair genes with radiation dose-response in patients with non-small cell lung cancer. |
| Q90825996 | Use of high and very high dose radiotherapy after radical prostatectomy for prostate cancer in the United States |
| Q92645701 | Vertebral body irradiation during chemoradiation therapy for esophageal cancer contributes to acute bone marrow toxicity |
| Q38711723 | What is changing in radiotherapy for the treatment of locally advanced nonsmall cell lung cancer patients? A review. |
| Q89720715 | Where is clinical research for radiotherapy going? Cross-sectional comparison of past and contemporary phase III clinical trials |
| Q86964709 | [Progression-free survival of patients with locally advanced NSCLC not improved by consolidation chemotherapy after concurrent chemoradiation] |
| Q88955706 | [Proton therapy not superior to IMRT in locally advanced NSCLC] |
Search more.